Back to search

Article

Unveiling Protection: A Meta-Analysis of Tixagevimab-Cilgavimab Prophylaxis in 28,950 Transplant Recipients and Immunocompromised Patients Against COVID-19

2024-08-27

Abstract excerpt

<h4>Background: </h4> This meta-analysis addresses the efficacy and safety of tixagevimab-cilgavimab as pre-exposure prophylaxis against COVID-19 in immunocompromised patients, particularly during the Omicron variant surge. Given the limited vaccine response in this population, alternative prophylactic strategies are critical. <h4>Methods: </h4> Following PRISMA guidelines, we comprehensively searched electronic...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b0b56a9e-00b2-54d0-97df-8775caa6c90a
DOI
10.22541/au.172473082.21291272/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Unveiling Protection: A Meta-Analysis of Tixagevimab-Cilgavimab Prophylaxis in 28,950 Transplant Recipients and Immunocompromised Patients Against COVID-19DOI 10.22541/au.172473082.21291272/v1
Tixagevimab/Cilgavimab for Prevention of COVID-19 during the Omicron Surge: Retrospective Analysis of National VA Electronic DataSemantic proximity
Systematic review of the clinical effectiveness of Tixagevimab/Cilgavimab for prophylaxis of COVID-19 in immunocompromised patientsSemantic proximity
Immunogenicity of COVID-19 mRNA Vaccines in Immunocompromised Patients: A Systematic Review and Meta-AnalysisSemantic proximity
Real World Effectiveness of Tixagevimab/cilgavimab (Evusheld) in the Omicron EraSemantic proximity
Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trialSemantic proximity
Pre-exposure prophylaxis for COVID-19 with Tix-agevimab/Cilgavimab in kidney transplant recipients in the Kraken variant (XBB.1.5) era: A Single-center ExperienceSemantic proximity
Tixagevimab/Cilgavimab for Treatment of Hospitalised COVID-19 Patients: A Randomised, Double-Blind, Phase 3 TrialSemantic proximity
Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population; A systematic review and meta-analysisSemantic proximity
Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From the CANOPY Clinical TrialSemantic proximity
Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2Semantic proximity
Uptake, effectiveness and safety of COVID-19 vaccines in the immunocompromised population: A population-based cohort study in EnglandSemantic proximity
Effectiveness of COVID-19 Vaccines at Preventing Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompromised Adults: An Observational Study of Real-World Data Across 10 US States from August-December 2021Semantic proximity
Select a neighboring publication to make it the new centre.